These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15080094)

  • 21. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
    Cabello Úbeda A; Sanz Moreno J; Williams F; Górgolas M
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e95-6. PubMed ID: 22005001
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy.
    Spiegel LR; Schrier PB; Shah HH
    Ren Fail; 2013 Sep; 35(8):1186-90. PubMed ID: 23883141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HIV agents. Trying times for tenofovir and abacavir.
    TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
    Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR
    J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
    Manosuthi W; Lueangniyomkul A; Mankatitham W; Chimsuntorn S; Tantanathip P; Thongyen S; Suntisuklappon B; Nilkamhang S; Sungkanuparph S
    J Infect; 2011 May; 62(5):406-9. PubMed ID: 21382413
    [No Abstract]   [Full Text] [Related]  

  • 27. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
    Gutiérrez S; Guillemi S; Jahnke N; Montessori V; Harrigan PR; Montaner JS
    Clin Infect Dis; 2008 Feb; 46(3):e28-30. PubMed ID: 18181733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].
    Walter M
    MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084
    [No Abstract]   [Full Text] [Related]  

  • 29. Summaries for patients. Treatment for resistant HIV-1 infection.
    Ann Intern Med; 2003 Sep; 139(5 Pt 1):I22. PubMed ID: 12965954
    [No Abstract]   [Full Text] [Related]  

  • 30. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
    MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
    Lacombe K; Pacanowski J; Meynard JL; Trylesinski A; Girard PM
    AIDS; 2005 Jul; 19(10):1107-8. PubMed ID: 15958845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
    Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
    Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
    Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral therapy and HIV/hepatitis B virus coinfection.
    Benhamou Y
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S98-103. PubMed ID: 14986281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir.
    Shere-Wolfe KD; Verley JR
    Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Parienti JJ
    J Antimicrob Chemother; 2009 May; 63(5):1080; author reply 1080-1. PubMed ID: 19158108
    [No Abstract]   [Full Text] [Related]  

  • 37. Triple combinations regimens for HIV.
    Lancet Infect Dis; 2003 Nov; 3(11):682. PubMed ID: 14603888
    [No Abstract]   [Full Text] [Related]  

  • 38. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
    Zhou H; Zheng Y; He Y; Gong G; Chen Z; Liu M; Yin W; Liu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):731-7. PubMed ID: 19734579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir poses risk with didanosine.
    AIDS Patient Care STDS; 2003 Jun; 17(6):309. PubMed ID: 12880494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.